IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
- 11 June 2024 - 1 mins read
Aggregated presentation by day and by market
| Statement of transactions in own shares from June 3 to June 7, 2024 | ||||||
| Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 03/06/2024 | FR0010259150 | 3 100 | 120,9943 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 04/06/2024 | FR0010259150 | 3 100 | 121,5713 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 05/06/2024 | FR0010259150 | 3 100 | 122,2187 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 06/06/2024 | FR0010259150 | 3 500 | 122,5593 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 07/06/2024 | FR0010259150 | 5 000 | 123,1718 | XPAR |
| TOTAL | 17 800 | 122,2274 | ||||
| 17 800 | ||||||
Attachment
11 July 2024
6 mins read
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
09 July 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
09 July 2024
1 mins read
Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
08 July 2024
1 mins read
Half-year statement of IPSEN liquidity agreement – 2024 06 30
02 July 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
02 July 2024
9 mins read
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
25 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
18 June 2024
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
10 June 2024
12 mins read
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
07 June 2024
6 mins read